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Linhardt).Heparin and heparan sulfate contain a rare 3-O-sulfoglucosamine residue critical for anticoagula-
tion and virus recognition, respectively. The glycosidic linkage proximate to this 3-O-sulfoglucos-
amine is resistant to cleavage by all heparin lyases (Heps). HepII has a broad speciﬁcity. The
crystal structure of the wild type HepII identiﬁed its active site and showed a close spatial proximity
between Asn405 and the 3-OH group of the bound glucosamine residue. In this study, we mutated
Asn405 to the less sterically demanding Ala405 or Gly405, which broadened the substrate speciﬁcity
of HepII and caused it to cleave the resistant linkage proximate to the 3-O-sulfoglucosamine residue.
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Heparin and heparan sulfate (HS) are negatively charged, linear
polysaccharides consisting of repeating uronic acid-glucosamine
disaccharide units. The major uronic acid components in heparin
and HS are iduronic acid (IdoA) and glucuronic acid (GlcA), respec-
tively. Heparin (Fig. 1A) is more highly sulfated than HS, with its
uronic acid residues commonly modiﬁed with 2-O-sulfo groups
and its glucosamine residuespredominantly substitutedwithN-sul-
fo and 6-O-sulfo groups and in rare caseswith 3-O-sulfo groups. The
signature 3-O-sulfo group containing glucosamine residue foundchemical Societies. Published by E
nic acid; IdoA, iduronic acid;
, 6-O-sulfo-N-acetylglucosa-
, antithrombin; Hep, heparin
liquid chromatography; MS,
Biology, Center for Biotech-
lytechnic Institute, Troy, NY
514 496 5143 (M. Cygler).
Cygler), linhar@rpi.edu (R.J.within the antithrombin (AT) binding sequence of heparin plays
an essential role in binding and activating AT [1–3] (Fig. 1A). In HS
a 3-O-sulfo group containing glucosamine residue is also contained
in the glycoprotein (gD) binding site required for Herpes simplex
virus type 1 (HSV-1) entry to cells [4–6].
Heparin and HS can be depolymerized through a b-elimination
mechanism by bacterial heparin lyases (Heps) (or heparinases), a
group of polysaccharide cleaving enzymes commonly expressed
and serving nutritional purposes in various microorganisms [7].
Among the identiﬁed three Heps, HepII from Pedobacter heparinus
(previously known as Flavobacterium heparinum) displays a un-
iquely wide range of substrate speciﬁcity, cleaving both heparin
and HS at the linkage between glucosamine residue and either
IdoA or GlcA residue having various sulfation patterns [8–10]. De-
spite this broad speciﬁcity, neither HepII nor any of the other cur-
rently known Heps are capable of cleaving the glycosidic linkage
(1, +1) when the proximate glucosamine residue at the reducing
end of the linkage (+2 subsite) contains a 3-O-sulfo group
(Fig. 1A) [11]. Recent studies on HepII in our laboratory have
determined the structure of HepII with and without complexed
HS oligosaccharide substrate or a disaccharide product [12,13].lsevier B.V. All rights reserved.
Fig. 1. HepII action on 3-O-sulfoglucosamine containing substrates. (A) Structure of a portion of the heparin chain containing an antithrombin binding site. Four sites are
shown that should be HepII cleavable based on the residues at the 1 +1 sites. Three of these are HepII cleavable (shown in green) and one, containing a 3-O-sulfoglucosamine
residue at subsite +2 is resistant (shown in red). (B) Chemical structures of used tetrasaccharide substrates. Tetrasaccharides a, b and c were prepared by exhaustively
digesting heparin with HepI. The four monosaccharides in each structure are labeled as 2 to +2 from non-reducing end to reducing end. The 3-O-sulfoglucosamine residue is
at subsite +2 and the putative HepII cleavage site is 1 +1.
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and GlcA occurred within the same catalytic site in HepII. Poten-
tial active site residues participating in the various mechanistic
steps of b-elimination have been identiﬁed along with their sug-
gested roles. Speciﬁcally, His406 was found to be responsible for
charge neutralization of the carboxyl group of uronic acid at the
cleavage site. Tyr257 and His202 serve as the catalytic bases in
the subsequent step by abstracting the proton of the C5 carbon
from GlcA-containing (HS) and IdoA-containing (heparin) sub-
strate, respectively [12]. In the crystal structure of HepII com-
plexed with oligosaccharides occupying +1 and +2 sites the 3-O-
hydroxy group of the glucosamine unit at the +2 subsite is buried
and making contacts with the protein sidechains. The present
study uses site-directed mutagenesis to perform protein engi-
neering on HepII to test our hypothesis that expanding the size
of the substrate-binding site near glucosamine 3-O-hydroxy
group will make this mutant able to cleave substrates containing
a 3-O-sulfoglucosamine residues at the +2 subsite. Several resi-
dues were mutated and the ability of the resulting enzymes to
act on resistant substrates containing a 3-O-sulfoglucosamine
residue was examined.
2. Materials and methods
2.1. Chemicals
Heparin and HS sodium salts were purchased from Celsus
Laboratories, Cincinnati, OH. Disaccharide standards of heparin
and HS were obtained from Iduron Co. Other chemicals includingchromatography and gel preparation reagents used in this work
were the same as previously reported [12,13].
2.2. Preparation of recombinant wild type and mutant HepII
The mutants were prepared using the previously described
expression plasmid containing HepII gene [13]. Site-directed
mutagenesis was performed by the QuickChange method using
Site-directed Mutagenesis Kit (Stratagene), according to the manu-
facturer’s protocol. Mutations were conﬁrmed by DNA sequencing.
All mutants were expressed in Escherichia coli BL21(DE3).
2.3. Preparation of the heparin-derived tetrasaccharide substrates
Heparin-derived tetrasaccharides were prepared as described in
previous literature [14]. Brieﬂy, heparin was exhaustively digested
by HepI in 50 mM sodium phosphate buffer, pH 7.4. The resulting
disaccharide components were removed by chromatography on a
100  5.0 cm Bio-Gel P10 column eluted with 0.2 M NaCl and the
oligosaccharide fractions were desalted on a 100  2.0 cm P2 col-
umn and lyophilized. The product mixture was fractionated on a
20  250 mm semipreparative strong anion exchange (SAX)-high
performance liquid chromatography (HPLC) column eluted with a
salt gradient with absorbance detected at 232 nm. Individual tetra-
saccharide peaks were desalted and further puriﬁed by repeated
separation on the same HPLC column. Purity of each tetrasaccha-
ride was determined to be >95% by analytical HPLC. Structures of
these tetrasaccharides were characterized by liquid chromatogra-
phy (LC)–mass spectrometry (MS) and 1D and 2D NMR [14–16].
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polyacrylamide gel electrophoresis (PAGE)
Heparin and HS were prepared to a ﬁnal concentration of
2 mg/ml in 50 mM sodium phosphate buffer, pH 7.0, and was
individually treated with 0.5 mg/ml WT or mutant HepII at
37 C overnight. Polyacrylamide gel was prepared in 22% and
5% of total acrylamide for resolving gel and stacking gel, respec-
tively. The gel was loaded with 5 lg of each polysaccharide
digestion sample and subjected to electrophoresis for 80 min at
200 V. The gel was visualized with 0.5% (w/v) Alcian blue in
2% (v/v) acetic acid solution.Fig. 2. Vicinity of the +2 sugar. (A) The stereo view of crystal structure of WT HepII with
are shown in thick lines while the neighboring sidechains are in thinner lines. (B) The N
residue at subsite +2. The asparagine sidechain of the wild type enzyme is painted in m2.5. Activity analysis of mutant HepII on deﬁned tetrasaccharide
substrates by LC–MS
Tetrasaccharide assays were performed each using 2 mg/ml of
WT or mutant HepII reacting with 0.15 mg/ml of tetrasaccharide
substrate in 50 mM sodium phosphate buffer, pH 7.0, at 37 C for
12 h. Control reactions were prepared using the same amount of
substrate with no enzyme. Inactivated protein, generated by heat-
ing the sample to 100 C, was removed by centrifugation at
13 000g for 30 min at the end of reaction. The supernatants con-
taining the reaction products were analyzed by LC–MS using an
Agilent 1200 LC/MSD instrument (Agilent Technologies, Inc. Wil-
mington, DE) equipped with an ion trap. An Acquity UPLC BEHbound disaccharide [13] occupying subsites +1 and +2. The disaccharide and Asn405
405G mutant was modeled with a disaccharide containing a 3-O-sulfoglucosamine
agenta to show that it would collide with the 3-O-sulfo group.
Fig. 3. PAGE (22%) analysis with alcian blue staining of polysaccharides digested
using HepII and HepII mutants. (Panel A) Markers (M) with degree of polymeri-
zation (dp) of major bands labeled, untreated heparin, heparin treated with WT
HepII, with HepII (N405A), with HepII (N405G), with HepII (N405A/H406A), with
HepII (N405G/H405A). (Panel B) Markers (M), untreated heparan sulfate, heparan
sulfate treated with WT HepII, with HepII (N405A), with HepII (N405G) with HepII
(N405A/H405A), with Hep (N405G/H406A), M, ladder of heparin oligosaccharide
standards [20].
Table 1
Observed and theoretical mass of the oligosaccharide substrates and products and their p
Fractions Found ions Observed
molecular mass
Theoretical
molecular mass
Ass
dpa
A1 [476.8]2 955.6 956.0 4
B1 [516.3]2 1034.6 1035.0 4
B2 [575.3] 576.6 576.9 2
B3 [457.4] 458.4 459.0 2
C1 [535.5]2 1073.0 1073.9 4
C2 [575.3] 576.6 576.9 2
C3 [495.3] 496.3 497.0 2
a Degree of polymerization.
b Conversion percentage is calculated by [product peak area/(product peak area + sub
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was used. Eluent A and B were water/acetonitrile (85:15) v/v,
and water/acetonitrile (35:65) v/v, respectively. Both eluents con-
tained 12 mM tributyl amine (TrBA) and 38 mM NH4OAc with pH
adjusted to 6.5 with HOAc. A gradient of solution A for 10 min fol-
lowed by a linear gradient from 10 to 40 min (0–50% solution B)
was used at ﬂow rate of 100 ll/min. The column efﬂuent entered
the source of the ESI-MS for continuous detection by MS. The elec-
trospray interface was set in negative ionization mode with a skim-
mer potential of40.0 V, a capillary exit of40.0 V, and a source of
temperature of 350 C, to obtain the maximum abundance of the
ions in a full scan spectrum (200–1500 Da). Nitrogen was used as
a drying (8 l/min) and nebulizing gas (40 psi).
3. Results and discussion
3.1. Structure of WT and modeled structure of Asn405 mutant HepII
bound with an HS disaccharide
The crystal structure of the catalytic site of WT HepII (Fig. 2A)
suggests a possible explanation for the inability of HepII to cleave
the polysaccharide or oligosaccharide substrate between 1 and
+1 subsites when a 3-O-sulfoglucosamine residue is located at the
+2 subsite (Fig. 1A) [13]. In the crystal structure, the 3-OH group of
the glucosamine at the +2 subsite was found to be pointing toward
the bottom of the substrate-binding cavity in very close proximity
to Asn405, His406, Tyr436 and Arg261. We speculated that if the
glucosamine residue at the +2 subsite contained a 3-O-sulfo group,
collision between this 3-O-sulfo group and the side chains of the
above amino acid residueswould sterically prevent proper position-
ing of the uronic acid reside at the +1 subsite, thus, preventing catal-
ysis (Fig. 2B).Of these,Arg261 is involved inhydrogenbonding to the
carboxylic group of +1 sugar while Tyr436 stacks against the hydro-
phobic face of +2 sugar; their replacement is likely to decrease sig-
niﬁcantly substrate binding and adversely affect activity. His406 is
also implicated in the enzymatic activity ofHepII and themost likely
residue tomutagenizewasAsn405. Replacement by glycinewithout
a sidechain opens up space for the additional sulfate group attached
to O3 (Fig. 2B). To test our hypothesis we performed site-directed
mutagenesis of Asn405 and also attempted to replace His406 by a
smaller sidechain. We prepared two single mutants N405A and
N405G and two double mutants, N405A/H406A N405G/H406A.
These mutants were expressed in E. coli with a His tag and puriﬁed
to homogeneity.
3.2. Activity of HepII mutant enzymes on polysaccharide substrates
The activity of these mutants was ﬁrst examined using heparin
and HS polysaccharides as substrates. Exhaustive treatment with
each enzyme (1–2 h) was monitored by PAGE (Fig. 3). Wild type
(WT) HepII served as a positive control completely digesting bothercent conversion on heparin lyase treatment.
ignment Conversion (%)b
Sequences WT N405A N405G
DUA-GlcNAc6S-GlcA-GlcNS3S 0 0 0
DUA-GlcNAc6S-GlcA-GlcNS3S6S 0 5 5
DUA-GlcNS3S6S
DUA-GlcNAc6S
DUA-GlcNS6S-GlcA-GlcNS3S6S 0 16 22
DUA-GlcNS3S6S
DUA-GlcNS6S
strate peak area)]  100 (Fig. 4).
Fig. 4. Extracted ion chromatography of tetrasaccharide a, b and c on treatment
with WT and mutant HepII by LC–MS analysis. (A) Tetrasaccharide a; (B)
tetrasaccharide b; (C) tetrasaccharide c. The four panels shown in each set of
chromatograms (from top to bottom) correspond to untreated tetrasaccharide, WT
treated tetrasaccharide, N405A tetrasaccharide, and N405G tetrasaccharide. Frac-
tions from each treatment are listed in Table 1.
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disaccharide and tetrasaccharide products [16]. The N405G mutant
enzyme afforded complete conversion on heparin and HS and
N405A enzyme showed a substantial decrease in the molecular
weight of both polysaccharides. The double mutants, N405A/
H406A and N405G/H406A, showed little or no activity on both sub-
strates with a barely observable activity towards HS. These results
are in agreement with our previous ﬁndings on the key role of
His406 in hydrogen-bonding the carboxylate oxygen of the cleav-
age site uronic acid for charge neutralization. Since His406 is
responsible for this step in the elimination of both GlcA-containing
(HS) and IdoA-containing (heparin) substrates, loss of enzymatic
activity is not unexpected for mutations at this site [13].
3.3. Activity of HepII mutant enzymes on deﬁned tetrasaccharide
substrates
Three structurally deﬁned tetrasaccharide substrates (a, b and c,
Fig. 1B) were next used to evaluate the effect of the Asn405 muta-
tion on catalysis. The tetrasaccharides were prepared through the
complete HepI depolymerization of heparin [16]. Each tetrasaccha-
ride contains a 3-O-sulfoglucosamine residue (+2 subsite) next to
the glycosidic uronic acid at the reducing end of the cleavage site
(1, +1) making these substrates resistant to WT HepII and all
other known Heps. Each tetrasaccharide contains a GlcA residue
at subsite +1 and either a 6-O-sulfo-N-sulfoglucosamine (GlcNS6S)
or 6-O-sulfo-N-acetylglucosamine (GlcNAc6S) residue at subsite
1. The tetrasaccharides were individually treated withWT or mu-
tant HepII under exhaustive reaction conditions, and any products
resulting from cleavage between 1 and +1 were identiﬁed by LC–
MS analysis. The observed and theoretical mass of the saccharide
substrates and products, their identity and the substrate conver-
sion percentage are summarized in Table 1.
WT HepII, showed no activity on any of the three tetrasaccha-
ride substrates tested and this experiment served as a negative
control. None of the Asn405 mutants were able to cleave the tetra-
saccharide a substrate into two disaccharide products. In contrast,
tetrasaccharide b and tetrasaccharide c served as substrates for
both the N405A and N405G mutants, being partially cleaved into
the two expected disaccharide products. The disaccharide product,
derived from the reducing end of both tetrasaccharides b and c,
had a molecular mass 576.6, corresponding to the 3-O-sulfo disac-
charide, DUA-3,6-O-sulfo-N-sulfoglucosamine (GlcNS3S6S). The
disaccharide products originating from the non-reducing end of
tetrasaccharide b and tetrasaccharide c had masses of 458.4
(DUA-GlcNAc6S) and 496.3 (DUA-GlcNS6S), respectively (Fig. 1B,
Table 1). The two double mutants, N405A/H406A and N405G/
H406A, failed to cleave any of the tetrasaccharide substrates (data
not shown). Even after extensive HepII treatment only 5% of tetra-
saccharide b substrate and 20% of tetrasaccharide c substrate were
converted to disaccharide products (Fig. 4, Table 1).
Extensive prior studies by others [17–19] on short oligosaccha-
rides, including tetrasaccharides, have demonstrated that HepII is
unable to cleave linkages (1 +1 subsite) with a proximate 3-O-
sulfated glucosamine at the +2 subsite. Speciﬁcally, tetrasaccharide
b and tetrasaccharide c have been reported to be resistant to cleav-
age by all known Heps due to the presence of the 3-O-sulfo group
[11,19]. The crystal structure of the active site of WT HepII clearly
shows a close proximity between Asn405 and the 3-OH group on
the +2 subsite glucosamine [12]. The results of the current study
clearly support the hypothesis that Asn405 sterically prevents
appropriate binding of substrates having a 3-O-sulfoglucosamine
residue at subsite +2 preventing cleavage of the 1 +1 subsite link-
age in these resistant substrates. The mutation of Asn405 to Ala
with a smaller side chain or Gly without a sidechain serves to fur-
ther reduce the substrate speciﬁcity of HepII. It is interesting tonote that the more highly sulfated substrate tetrasaccharide c is
a better HepII (N405A or N405G) substrate than tetrasaccharide
b presumably due to enhanced binding to these mutant enzymes.
In contrast, tetrasaccharide a is not a substrate possibly owing to
the decreased sulfation at its reducing end +2 glucosamine residue
2466 W. Zhao et al. / FEBS Letters 585 (2011) 2461–2466adversely impacting its binding to the mutant HepII enzymes. Tet-
rasaccharide b and tetrasaccharide c comprise a large proportion of
the tetrasaccharides produced in Hep-catalyzed depolymerization
of heparin, consistent with the high frequency of these sequences
within the AT binding site of heparin. Thus, the present work dem-
onstrates the potential of protein engineering to create new en-
zymes for use as tools for sequence analysis. Additional work
will be required to enhance the activity and stability of such mu-
tant enzymes before they can be routinely used in heparin analysis.
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